On April 13, an Israeli therapeutic company has formulated a placenta-cell based therapy that was found to have completely cured six critical COVID-19 patients.
A report according to Israel-based Pluristem Therapeutics Inc. stated that the six patients had been suffering inflammations and acute respiratory failure linked to COVID-19 for a week and were considered all considered to be “high risk for mortality.”
According to Pluristem, all six patients survived. Four of them showed rapid improvement in their respiratory conditions, and three patients with pre-existing cardiovascular and kidney issues have also been showing recovery.
Placenta-based cells are cells that trigger the body’s regenerative mechanisms to revitalize the healing of damaged tissue.
Articles you might like: Coronavirus: what is Pluristem’s placenta-based cell therapy? HEALTHCARE WORKERS Getting Sicker than their PATIENTS
In addition to this, the company adds that these cells can be reproduced and given to patients without matching them with the patient’s existing tissue.
However, in people with a dysfunctional immune system, this over-revitalizing of the immune system could trigger the release of too many immune cells, further damaging the tissue.
Pleased with the initial outcome, Pluristem plans to initiate the multinational clinical treatment of COVID-19 with the use of the new placenta-based therapy.
Currently, the company is in discussion with regulators in Europe and the United States “to define our clinical strategy for COVID-19”.